LifeTech Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

LifeTech Scientific wird ein jährliches Gewinn- und Umsatzwachstum von 20.5% bzw. 16.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.8% betragen.

Wichtige Informationen

20.5%

Wachstumsrate der Gewinne

20.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	35.2%
Wachstumsrate der Einnahmen	16.8%
Zukünftige Eigenkapitalrendite	10.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	31 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

Jul 05

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Dec 25

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

Nov 28

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

Nov 03

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

Oct 14

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Jul 15

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

Jun 30

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Jun 15

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Apr 03

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Mar 15

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Jan 22

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Dec 19

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Dec 06

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

Oct 12

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

Sep 13

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

Aug 28

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Aug 13

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Jun 08

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

May 26

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

May 11

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Feb 21

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

Jan 26

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Nov 25

Gewinn- und Umsatzwachstumsprognosen

SEHK:1302 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1,774	399	N/A	406	1
12/31/2024	1,474	328	N/A	325	1
12/31/2023	1,267	263	125	418	N/A
9/30/2023	1,224	297	84	393	N/A
6/30/2023	1,182	331	43	367	N/A
3/31/2023	1,139	328	48	378	N/A
12/31/2022	1,097	325	53	388	N/A
9/30/2022	1,058	314	86	437	N/A
6/30/2022	1,019	303	119	486	N/A
3/31/2022	972	298	108	464	N/A
12/31/2021	925	292	98	441	N/A
9/30/2021	878	307	147	436	N/A
6/30/2021	830	322	196	432	N/A
3/31/2021	736	269	188	385	N/A
12/31/2020	642	216	180	339	N/A
9/30/2020	638	176	154	303	N/A
6/30/2020	633	136	128	268	N/A
3/31/2020	651	132	144	271	N/A
12/31/2019	669	129	161	275	N/A
9/30/2019	644	138	146	252	N/A
6/30/2019	618	146	132	229	N/A
3/31/2019	588	134	101	206	N/A
12/31/2018	557	121	70	182	N/A
9/30/2018	518	134	71	190	N/A
6/30/2018	480	147	72	199	N/A
3/31/2018	445	155	37	177	N/A
12/31/2017	409	163	2	155	N/A
9/30/2017	391	171	N/A	146	N/A
6/30/2017	373	178	N/A	136	N/A
3/31/2017	363	162	N/A	132	N/A
12/31/2016	353	146	N/A	127	N/A
9/30/2016	336	201	N/A	121	N/A
6/30/2016	319	256	N/A	115	N/A
3/31/2016	315	129	N/A	130	N/A
12/31/2015	312	2	N/A	144	N/A
9/30/2015	304	-41	N/A	113	N/A
6/30/2015	296	-84	N/A	81	N/A
3/31/2015	289	-83	N/A	50	N/A
12/31/2014	283	-81	N/A	20	N/A
9/30/2014	280	-151	N/A	N/A	N/A
6/30/2014	258	-209	N/A	6	N/A
3/31/2014	248	-89	N/A	N/A	N/A
12/31/2013	231	-66	N/A	35	N/A
9/30/2013	209	-53	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1302Das prognostizierte Gewinnwachstum (20.5% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: 1302Die Erträge des Unternehmens (20.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (11.8% pro Jahr).

Hohe Wachstumserträge: 1302Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 1302Die Einnahmen des Unternehmens (16.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).

Hohe Wachstumseinnahmen: 1302Die Einnahmen des Unternehmens (16.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 1302Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.8%).

LifeTech Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023

Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?

Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021)

Investor sentiment improved over the past week

LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Insufficient new directors

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US

First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021)

LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Insufficient new directors

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Full year 2021 earnings: EPS and revenues miss analyst expectations

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA

Is LifeTech Scientific (HKG:1302) A Risky Investment?

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020)

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Investor sentiment deteriorated over the past week

LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

Investor sentiment improved over the past week

Non-Executive Director has left the company

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: HK$3.62

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Lifetech Scientific Corporation Announces Admission to Special Examination and Approval Procedure for Innovative Medical Devices in Respect of Artery Stent Graft System

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

New 90-day high: HK$5.46

New 90-day high: HK$4.43

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Gl Trade Investment III L.P. and Gao Ling Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. acquired 10.67% stake in LifeTech Scientific Corporation (SEHK:1302) from Central Huijin Investment Ltd.

Market bids up stock over the past week

New 90-day high: HK$2.99

Market bids up stock over the past week

New 90-day low: HK$2.05

First half earnings released

LifeTech Scientific Corporation to Report First Half, 2020 Results on Aug 28, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken